Literature DB >> 3258957

Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis.

J L Trotter, D B Clifford, C B Anderson, R C van der Veen, B C Hicks, G Banks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3258957     DOI： 10.1056/nejm198805053181816

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  F T Rotteveel; C J Lucas
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 2.  Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

Authors:  Robert K McNamara; Francis E Lotrich
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

3.  Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Authors:  S Inogés; J Merino; E Bandrés; P De Castro; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

4.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

5.  Local anaesthetic-like effect of interleukin-2 on muscular Na+ channels: no evidence for involvement of the IL-2 receptor.

Authors:  A Kaspar; H Brinkmeier; R Rüdel
Journal:  Pflugers Arch       Date:  1994-01       Impact factor: 3.657

Review 6.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

7.  Interleukin-2 inhibits sodium currents in human muscle cells.

Authors:  H Brinkmeier; A Kaspar; H Wiethölter; R Rüdel
Journal:  Pflugers Arch       Date:  1992-04       Impact factor: 3.657

8.  Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.

Authors:  M Ott; L Demisch; W Engelhardt; P A Fischer
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

9.  Lymphokines and soluble interleukin-2 receptors in juvenile chronic arthritis. Clinical and laboratory correlations.

Authors:  K Müller; F K Pedersen; A Wiik; K Bendtzen
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.

Authors:  Y Zhang; M McClellan; L Efros; D Shi; B Bielekova; M T Tang; V Vexler; J P Sheridan
Journal:  Mult Scler       Date:  2013-07-11       Impact factor: 6.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.